Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials-Reference-Cited by-同舟云学术

Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials

Published:2017-05-13 Issue:2 Volume:7 Page:243-248
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Simpson Eric L.

Funder

Sanofi

Regeneron Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

http://link.springer.com/content/pdf/10.1007/s13555-017-0181-6.pdf

Reference9 articles.

1. Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham N, et al. Patient burden of moderate-to-severe atopic dermatitis: insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491–8.

2. Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50.

3. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.

4. Szende A, Janssen B, Cabases J, editors. Self-reported Population Health: An International Perspective Based on EQ-5D. Dordrecht: Springer; 2014.

5. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11–8.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Incorporating Future Mandatory Price Reductions with Generic Drug Entry on the Cost-Effectiveness of New Drugs: A Policy Simulation Study of Dupilumab in Atopic Dermatitis Treatment;Healthcare;2024-05-02

2. Cost‐effectiveness analysis of abrocitinib compared with standard of care in adult moderate‐to‐severe atopic dermatitis in Japan;The Journal of Dermatology;2024-04-22

3. Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain;PharmacoEconomics - Open;2024-01-18

4. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis;HEALTH TECHNOL ASSES;2024

5. Managing a Patient Presenting With Chest Pain and Gastrointestinal Complaints Using Dupilumab;Cureus;2023-10-04